Figure 7.

Sclerostin activates PDGFR signaling and inhibits differentiation of primary osteoblasts. (a) Primary mouse osteoblasts were pre-treated with 10 μg ml⁻¹ sclerostin or its vehicle and stimulated or not with 100 ng ml⁻¹ BMP2 for 48 h before evaluation of ALP activity. (b) Western blot analyses of PDGFR signaling in primary mouse osteoblasts incubated with 10 μg ml⁻¹ sclerostin for different periods. *P< 0.01 for BMP2 versus its vehicle; +P<0.01 for SOST versus its vehicle.